Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Breast Cancer: Update Bulletin [December 2015]

Product Code:
596200421
Publication Date:
December 2015
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events happening in breast cancer: In this update KOLs reflect on whether TapImmune’s strategy of targeting the folate receptor alpha will prove useful in patients with triple-negative breast cancer (TNBC); expert reactions to early-stage data for Synthon’s SYD985; Stellar Biotechnologies’ and Amaran Biotechnology’s OBI-822; an update on Galena Biopharma’s Neuvax; the recent award of FDA breakthrough therapy designation for Eli Lilly’s abemaciclib, as well as the merits of the ongoing KEYNOTE-119 trial of Merck & Co.’s pembrolizumab in TNBC.

Key Questions Answered in this Update Bulletin:

  • How do KOLs feel about TapImmune’s strategy of targeting the folate receptor alpha with a vaccine?
  • Do they have any concerns about the prevalence of folate receptor alpha in breast cancer patients?
  • What are KOLs first impressions of Synthon’s SYD985, a human epidermal growth factor receptor 2 (HER2)-targeting antibody-drug conjugate (ADC) currently in Phase I trials?
  • Are there any concerns about the current clinical trial strategy?
  • Do they foresee any problems with the inclusion of an ADC in the therapy?
  • How do KOLs feel about the potential of Stellar Biotechnologies and Amaran Biotechnology’s OBI-822 in the breast cancer setting
  • What do KOLs think about Galena Biopharma’s decision to target NeuVax (nelipepimut-S) in a Phase II trial involving patients diagnosed with Ductal Carcinoma in Situ (DCIS)?
  • Do they believe Neuvax could also hold promise in the separate Phase III PRESENT trial, which includes patients with operable early-stage, node-positive breast cancer?
  • How did KOLs react to news that Eli Lilly’s abemaciclib, a cyclin-dependent kinase (CDK) 4 and 6 inhibitor, had received breakthrough therapy designation from the FDA?
  • How do KOLs think abemaciclib compares to Ibrance (palbociclib)?
  • What do KOLs think about the launch of Merck & Co.’s Phase III KEYNOTE-119 trial, which will compare single agent pembrolizumab with single agent chemotherapy of physicians choice in patients with metastatic triple-negative breast cancer?
  • Are there any concerns regarding the use of pembrolizumab in this patient population?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved